Cargando…

Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses

INTRODUCTION: Patients with atherosclerotic cardiovascular disease (ASCVD), especially those with recent (< 1 year) acute coronary syndrome (ACS), are at high risk for recurrent cardiovascular events. This risk can be reduced by lowering low-density lipoprotein cholesterol (LDL-C) levels. A compr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaya, Fadia Tohme, Sing, Krystal, Milam, Robert, Husain, Fasahath, del Aguila, Michael A., Patel, Miraj Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266788/ https://www.ncbi.nlm.nih.gov/pubmed/31724105 http://dx.doi.org/10.1007/s40256-019-00379-9

Ejemplares similares

Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States
por: Klimchak, Alexa C., et al.
Publicado: (2020)

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins
por: McQueen, R. Brett, et al.
Publicado: (2022)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
por: Rea, Federico, et al.
Publicado: (2021)

Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta‐Analysis
por: Zhang, Xin‐Lin, et al.
Publicado: (2019)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV
por: Bennett, Matthew T, et al.
Publicado: (2007)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Meta-analysis and trial sequential analysis of ezetimibe for coronary atherosclerotic plaque compositions
por: Chai, Bofeng, et al.
Publicado: (2023)

Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2021)

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
por: Journath, Gunilla, et al.
Publicado: (2017)

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
por: Desai, Nihar R., et al.
Publicado: (2022)

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
por: Faridi, Kamil F., et al.
Publicado: (2023)

Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks
por: Kao, Yu-Cheng, et al.
Publicado: (2021)

Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
por: Choi, Su-Yeon, et al.
Publicado: (2020)

Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
por: Pradhan, Akshyaya, et al.
Publicado: (2020)

Effect of natural honey on lowering lipid profile
por: Alkhalifah, Mohammed K., et al.
Publicado: (2021)

Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
por: Choi, Young Hwan, et al.
Publicado: (2014)

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients
por: Saeedi, Ramesh, et al.
Publicado: (2015)

Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies
por: Wang, Yang, et al.
Publicado: (2022)

Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
por: Tie, Chunmiao, et al.
Publicado: (2015)

Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
por: Ai, Cong, et al.
Publicado: (2018)

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects
por: Rosen, Jeffrey B, et al.
Publicado: (2013)

Plasma lipoprotein (a) and tissue plasminogen activator are associated with increased risk of atherosclerotic cardiovascular disease
por: Mayyas, Fadia, et al.
Publicado: (2022)

Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome
por: Ohbu-Murayama, Kyoko, et al.
Publicado: (2015)

Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2019)

Effectiveness of dietetic consultation for lowering blood lipid levels in the management of cardiovascular disease risk: A systematic review and meta‐analysis of randomised controlled trials
por: Ross, Lynda J., et al.
Publicado: (2019)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

A scientific correlation between dystemprament in Unani medicine and diseases: a systematic review
por: Miraj, Sepideh, et al.
Publicado: (2016)

A Systematic Review of Anti-malarial Properties, Immunosuppressive Properties, Anti-inflammatory Properties, and Anti-cancer Properties of Artemisia Annua
por: Alesaeidi, Samira, et al.
Publicado: (2016)

A systematic review study of therapeutic effects of Matricaria recuitta chamomile (chamomile)
por: Miraj, Sepide, et al.
Publicado: (2016)

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2022)

Comparative Study of Ezetimibe and Atorvastatin Alone and in Combination on Lipid Profile in Rats
por: Prasad, Anju, et al.
Publicado: (2013)

Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom
por: Reynolds, Timothy Mark, et al.
Publicado: (2021)

Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
por: Sasidharan, Akhil, et al.
Publicado: (2022)

Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
por: Le, Ngoc‐Anh, et al.
Publicado: (2015)

Fungal biotransformation of ezetimibe
por: Pervaiz, Irfan, et al.
Publicado: (2014)

Single-incision laparoscopy surgery: a systematic review
por: far, Sasan Saeed, et al.
Publicado: (2016)

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
por: Cannon, Christopher P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i4a1nt8ufpqkbd373pght3osqi